Skip to main content
Fig. 10 | Retrovirology

Fig. 10

From: HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial

Fig. 10

Plasma viremia up to week 48 in vaccinees and placebo non compliant to therapy. Percentage of vaccinees and anti-Tat Ab-negative placebos non-compliant to cART with detectable plasma viremia (upper panel), and plasma viremia values (log10 copies/mL) in patients with detectable viral load at each study visit (lower panel)

Back to article page

Retrovirology

ISSN: 1742-4690

Contact us